← Russell 3000 cross-section

UFPT UFP TECHNOLOGIES INC

Trailing twelve months to 2026-06-30 · as filed 2026-08-06, not restated
Healthcare

Scale

Market cap
$2.3bn
Revenue TTM
$632m
Net income TTM
$72m
Free cash flow
Composite score
49.9
Sector rank
#1553

Valuation

P / E
32.4
EV / EBITDA
20.1
EV / sales
3.9
FCF yield
Earnings yield vs 10-yr
-1.64pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
11.4%
EBITDA margin
19.1%
ROE
15.6%
ROIC
17.3%
Revenue growth
7.3%

Insider activity, last 90 days

Net open-market
$-12.92m
Buyers
0
Sellers
5

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Net sales for the six months ended June 30, 2026 increased 9.6% to $328.2 million from $299.3 million in the same period last year. The increase was largely due to growth in sales in our Surfaces and Support, Cardiovascular, Infection Control, and Orthopedics sub-markets. Organic sales growth for the three and six months ended June 30, 2026 was 12.4% and 6.8%, respectively. Net sales from our largest two customers were 26.2% and 21.0% of our total net sales during the three months ended June 30, 2026, respectively, and 25.5% and 21.5% of our total net sales during the six months ended June 30, 2026, respectively. …UFP TECHNOLOGIES INC, 10-Q, period ended 2026-06-30, filed 2026-08-06

Read the full passage →